BRS Completes Recapitalization of Seroyal International Inc.
January 11, 2005
NEW YORK, January 11, 2005 — Bruckmann, Rosser, Sherrill & Co. (“BRS”) announced today the completion of a recapitalization of Seroyal International Inc. and its affiliate Seroyal USA Inc. (collectively “Seroyal” or the “Company”) with the founder of Seroyal, Rosetta Raso. American Capital Strategies Ltd. also participated in the transaction.
Seroyal, headquartered in Richmond Hill, Ontario, markets and distributes high-quality nutritional supplements and homeopathic remedies to health care practitioners in Canada and the U.S. The Company’s practitioner customers include naturopathic, chiropractic and medical doctors, nutritionists, homeopaths, acupuncturists, veterinarians and dentists. Seroyal markets nutritional supplements under its proprietary Genestra brand and homeopathic remedies manufactured by Unda SA of Belgium (under the Unda brand) through exclusive distributorship agreements for Canada and the U.S. Both brands are highly regarded within the health care practitioner community.
BRS is a New York based private equity investment firm with approximately $1.2 billion under management. BRS was founded in 1995 and has since invested in over 20 companies in the following industries: restaurants, consumer goods, specialty retail, recreation/leisure, apparel, home furnishings, industrial and commercial services, commercial equipment manufacturing, wholesale distribution and healthcare services. BRS makes leveraged buyout, recapitalization and growth capital investments in companies with superior management, predictable cash flow, strong market share and growth potential. All management teams of BRS companies are equity investors in their businesses.